CN109954052A - 一种具有抗氧化活性的组合物 - Google Patents
一种具有抗氧化活性的组合物 Download PDFInfo
- Publication number
- CN109954052A CN109954052A CN201711430886.3A CN201711430886A CN109954052A CN 109954052 A CN109954052 A CN 109954052A CN 201711430886 A CN201711430886 A CN 201711430886A CN 109954052 A CN109954052 A CN 109954052A
- Authority
- CN
- China
- Prior art keywords
- composition
- antioxidant activity
- present
- release agent
- antioxidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 claims abstract description 21
- 235000009754 Vitis X bourquina Nutrition 0.000 claims abstract description 17
- 235000012333 Vitis X labruscana Nutrition 0.000 claims abstract description 17
- 235000014787 Vitis vinifera Nutrition 0.000 claims abstract description 17
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 16
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 15
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 12
- 206010041303 Solar dermatitis Diseases 0.000 claims abstract description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 230000003064 anti-oxidating effect Effects 0.000 claims abstract description 6
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 238000013270 controlled release Methods 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 239000007938 effervescent tablet Substances 0.000 claims abstract description 5
- 239000000839 emulsion Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims abstract description 5
- 239000007924 injection Substances 0.000 claims abstract description 5
- 238000002347 injection Methods 0.000 claims abstract description 5
- 239000006187 pill Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 238000013268 sustained release Methods 0.000 claims abstract description 5
- 239000012730 sustained-release form Substances 0.000 claims abstract description 5
- 239000006188 syrup Substances 0.000 claims abstract description 5
- 235000020357 syrup Nutrition 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims abstract description 5
- 230000008685 targeting Effects 0.000 claims abstract description 5
- 244000294611 Punica granatum Species 0.000 claims abstract description 4
- 239000006071 cream Substances 0.000 claims abstract description 3
- 240000006365 Vitis vinifera Species 0.000 claims abstract 3
- 239000000725 suspension Substances 0.000 claims abstract 2
- 235000006708 antioxidants Nutrition 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 235000013376 functional food Nutrition 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract 2
- 108010012715 Superoxide dismutase Proteins 0.000 abstract 2
- 210000002966 serum Anatomy 0.000 abstract 2
- 102000003992 Peroxidases Human genes 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 108040007629 peroxidase activity proteins Proteins 0.000 abstract 1
- 241000219095 Vitis Species 0.000 description 14
- 241000219991 Lythraceae Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000003925 brain function Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000006587 Glutathione peroxidase Human genes 0.000 description 2
- 108700016172 Glutathione peroxidases Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229940087603 grape seed extract Drugs 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 239000001717 vitis vinifera seed extract Substances 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007131 anti Alzheimer effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- -1 common cancer Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种具有抗氧化活性的组合物,该发明主要由以下两种药物组成:葡萄籽、石榴籽,该两种药物均为食品工业中常用原料,具有极高的安全性,且效果明显。本发明的抗氧化组合物具有较强的抗氧化作用,能够显著性提高血清超氧化物歧化酶(SOD)、谷光苷肽过氧化物酶(GSH‑PX)活力和显著性降低血清的丙二醛(MDA)含量。该组合物可制成散剂、片剂、颗粒剂、丸剂、胶囊剂、泡腾片、糖浆剂、膏滋、乳剂、合剂、混悬剂、缓释剂、控释剂、靶向制剂或针剂,本发明能明显增强机体抗氧化活性,并能有效预防、治疗日光性皮炎和阿尔兹海默症等病症,本发明可用于与此相关的药品和保健食品开发。
Description
技术领域
本发明涉及一种具有抗氧化活性的组合物。
背景技术
现在,越来越多的人害怕衰老,而研究显示抗氧化是预防衰老的重要步骤,因为过多的自由基会影响代谢功能,并会引起不同程度的健康问题,如果能够消除过多的氧化自由基,那么就能有效预防自由基引起的老化相关的疾病,如常见的癌症、老年痴呆、关节炎等。
生物体内存在能清除自由基的酶类或非酶类物质所共同组成的防御系统,此系统属于内源性抗氧化防御系统。其大致分为两大类:第一类是抗氧化酶,主要包括超氧化物歧化酶(SOD)、过氧化氢酶(CAT)以及谷胱甘肽过氧化物酶(GSH-PX)。第二类是非酶类抗氧化剂,包括 VC、VE、β-胡萝卜素、谷胱甘肽等。
葡萄籽是整粒葡萄质量的4% ~ 6%,近年来,随着对葡萄籽研究的不断深入,发现葡萄籽中多种成分具有极高的营养价值和保健价值。葡萄籽中含有丰富的水、蛋白质、氨基酸、矿物质、脂肪、碳水化合物和膳食纤维等多种营养素,此外还含有多种具有较高的抗氧化作用以及保护大脑的作用的功能性成分,如原花青素、葡萄籽油、白藜芦醇、维生素、单宁等。
葡萄籽提取液,又称红酒多酚,它有抗氧化功效,亦可稳定人体肌肤必须的胶原蛋白质,维持弹力素,葡萄籽中的花青配糖体,抗氧化能力极高,是维生素C的20倍、维生素E的50倍。
石榴(Punica granatum L.)性味酸、甘、涩、温,入肾、大肠经。具有调理胃火、消食、止泻之功效,石榴籽具有降低糖尿病血糖、抗腹泻的功效,并具有显著的抗人体乳腺癌和抗氧化活性,可用于预防和治疗乳腺癌及动脉硬化引起的心脏病,具有延缓人体衰老的功效,上述生理药理活性都与其所含抗氧化性成分相关。
石榴籽多酚是一种强抗氧化剂,石榴籽能促进关节的适应性和皮肤的弹性,保护心血管,抗炎症和减缓运动损伤,减缓因糖尿病引起的视力损伤和促进视觉灵敏度的提高,促进脑功能等多重药理作用。
发明内容
为了解决上述技术问题,本发明提供一种具有抗氧化活性的组合物。
本发明一种具有抗氧化活性的组合物,该抗氧化组合物由葡萄籽和石榴籽及其提取物。
本发明一种具有抗氧化活性的组合物,优选各个组分为:葡萄籽(20%--80%),石榴籽(20%--80%),以及采用以下列辅料中的一种或几种,微晶纤维素,预胶化淀粉,大豆油,乳糖,蔗糖,糊精等制成不同剂型。
本发明一种具有抗氧化活性的组合物,其特征在于所述组合药物的剂型为片剂、颗粒剂、丸剂、胶囊剂、泡腾片、糖浆剂、膏滋剂、软胶囊、乳剂、散剂、缓释剂、控释剂、靶向制剂或针剂。
本发明一种具有抗氧化活性的组合物,与现有技术相比本发明的有益效果为本发明不仅具有强抗氧化作用而且在预防日光性皮炎、阿尔兹海默症、抗癌等疾病中有巨大的用途,此组合药物具有良好的开发前景,与现有的抗氧化药物相比具有原料来源方便、安全性高、用药量小、疗效显著、无毒副作用等特点。
具体实施方式
下面结合实施例,对本发明的具体实施方式作进一步详细描述,以下实施例用于说明本发明,但不用来限制本发明的范围。
实施例1:一种具有抗氧化活性的组合物,优选各个组分为:葡萄籽75%,石榴籽25%,配合适量微晶纤维素,预胶化淀粉,大豆油,乳糖,蔗糖,糊精等。
本发明一种具有抗氧化活性的组合物,其特征在于所述组合药物的剂型为片剂、颗粒剂、丸剂、胶囊剂、泡腾片、糖浆剂、膏滋剂、软胶囊、乳剂、散剂、缓释剂、控释剂、靶向制剂或针剂。
本发明一种具有抗氧化活性的组合物,与现有技术相比本发明的有益效果为本发明不仅具有强抗氧化作用而且在预防日光性皮炎、阿尔兹海默症、抗癌等疾病中有巨大的用途,此组合药物具有良好的开发前景,与现有的抗氧化药物相比具有原料来源方便、安全性高、用药量小、疗效显著、无毒副作用等特点。
实施例2:一种具有抗氧化活性的组合物,优选各个组分为:葡萄籽65%,石榴籽35%,配合适量微晶纤维素,预胶化淀粉,大豆油,乳糖,蔗糖,糊精等。
本发明一种具有抗氧化活性的组合物,其特征在于所述组合药物的剂型为片剂、颗粒剂、丸剂、胶囊剂、泡腾片、糖浆剂、膏滋剂、软胶囊、乳剂、散剂、缓释剂、控释剂、靶向制剂或针剂。
本发明一种具有抗氧化活性的组合物,与现有技术相比本发明的有益效果为本发明不仅具有强抗氧化作用而且在预防日光性皮炎、阿尔兹海默症、抗癌等疾病中有巨大的用途,此组合药物具有良好的开发前景,与现有的抗氧化药物相比具有原料来源方便、安全性高、用药量小、疗效显著、无毒副作用等特点。
本发明一种具有抗氧化活性的组合物中各组分的药理性质分析:葡萄籽1、抗氧化:提取物是迄今发现的植物来源的最高效的抗氧化剂之一,体内和体外试验表明,葡萄籽提取物的抗氧化效果,是维生素C的20倍、维生素E的50倍。超强的抗氧化效率具有清除自由基、提高人体免疫力的强力效果,葡萄籽提取物对人体抗氧化,提高免疫力有极佳的效果。2、降低血脂:葡萄籽提取物富含100多种有效物质,其中不饱和脂肪酸——亚油酸(是一种人体必需但不能合成的)占68%-76%居油料作物之首,它由不饱和到饱和状态要消耗20%的胆固醇,能够有效的降低血脂。3、防护人体皮肤:免受自由基侵袭,此功能使皮肤增加弹性,不受恶劣环境侵害。4、保护大脑:葡萄籽精华素可以非常容易地穿越血脑屏障,是一种特别有效的抗氧化物质,而且能够高度集中在大脑和神经组织中,这一特性使它成为大脑最为理想的抗氧化物质。此外,葡萄籽还有抗过敏、保护血管、保护组织、保护眼睛等多重作用。
石榴籽来源于石榴的种籽。功能作用:石榴籽多酚是一种强抗氧化剂,能促进关节的适应性和皮肤的弹性,保护心血管,抗炎症和减缓运动损伤,减缓因糖尿病引起的视力损伤和促进视觉灵敏度的提高,促进脑功能等多重药理作用,石榴籽具有降低糖尿病血糖、抗腹泻的功效,并具有显著的抗人体乳腺癌和抗氧化活性,可用于预防和治疗乳腺癌及动脉硬化引起的心脏病,具有延缓人体衰老的功效,上述生理药理活性都与其所含抗氧化性成分相关。
石榴籽能促进关节的适应性和皮肤的弹性,保护心血管,抗炎症和减缓运动损伤,减缓因糖尿病引起的视力损伤和促进视觉灵敏度的提高,促进脑功能等多重药理作用。
本发明一种具有抗氧化活性的组合物药物抗氧化活性分析,选用健康雄性小鼠50只,体重 22 ~ 28 g,在饲养室适应性喂养7 d后,按体重随机分为 5组,各组分别为:正常对照组(NC)、维生素C组、低剂量组 (LD)、中剂量组 (MD )、高剂量组 (HD),各组均饲以基础饲料、自由饮水。组方试验组每天定时经口灌胃 1 次, 正常对照组灌胃等量的蒸馏水,持续 30 d。定期换水、垫料,每周称 1次体重。在试验期间,观察试验动物的行为表现。试验结束后,大鼠隔夜禁食,不限制饮水。取下腔静脉血进行处理,观察指标 :①超氧化物歧化酶 (SOD)②谷胱甘肽过氧化物酶 (GSH-PX)的活性测定③丙二醛 (MDA)含量。
表1 组合物对小鼠SOD活力的影响
组别 | SOD活力(U/mg) |
空白对照组 | 158.11±37.01 |
维生素C | 203.23±23.56* |
低剂量组 | 209.29±28.19* |
中剂量组 | 252.22±29.54** |
高剂量组 | 325.20±78.48** |
本发明由表1可以看出,说明低剂量、中剂量和高剂量组小鼠SOD活力数值均明显提高,其中中剂量组和高剂量组对小鼠SOD活力有显著性提高,且无任何不良反应。
表2 组合物对小鼠GSH-PX活力的影响
组别 | 肝GSH-PX活力(U/mg) |
空白对照组 | 545.59±38.61 |
维生素C | 720.23±28.43* |
低剂量组 | 749.65±96.20* |
中剂量组 | 832.25±45.65** |
高剂量组 | 1021.35±93.84** |
本发明由表2可以看出,说明低剂量、中剂量和高剂量组小鼠GSH-PX活力数值均明显提高,其中中剂量组和高剂量组对小鼠GSH-PX活力有显著性提高,且无任何不良反应。
表3 组合物对小鼠MDA含量的影响
组别 | MDA含量 |
对照组 | 5.72±0.31 |
维生素C | 4.39±0.94* |
低剂量组 | 4.19±0.84* |
中剂量组 | 3.79±0.22* |
高剂量组 | 2.90±0.32** |
本发明由表3可以看出,说明低剂量、中剂量和高剂量组小鼠MDA含量数值均明显降低,其高剂量组对小鼠MDA含量有显著性降低,且无任何不良反应。
本发明一种具有抗氧化活性的组合物抗阿尔兹海默症活性分析,取雄性小鼠50只,随机分为模型组、组合物低剂量组、组合物中剂量组和组合物高剂量组共5组,每组10只动物;另取雄性小鼠10只作为正常对照组。正常对照组和模型组给同体积双蒸水,组合物低、中、高剂量给相应浓度的药液,阳性对照组给指定药物药液,连续灌胃给药两个月。组合物对小鼠空间学习与记忆能力的影响自给药开始第50天,进行Morris水迷宫测试。测试內容主要包括两部分:空间定位航行实验(Place navigation)和空间探索实验(Spatialprobe)。
表4组合药物对小鼠定位航行实验逃避潜伏期的影响(`x±s,n=6)
组别 | 剂量g/kg | 第一天 | 第二天 | 第三天 | 第四天 | 第五天 |
正常组 | - | 117.50±2.50 | 75.83±20.04 | 67.17±23.70 | 58.71±20.02 | 52.67±11.11 |
模型组 | - | 125.00±1.31* | 130.00±0.00** | 128.00±0.00** | 117.00±0.00** | 123.00±0.00** |
低剂量组 | 0.05 | 130.00±1.63* | 115.67±17.31* | 98.33±10.84* | 87.67±18.84* | 76.17±8.66* |
中剂量组 | 0.10 | 128.00±1.27* | 117.21±11.32* | 84.25±11.34* | 80.89±20.11* | 69.81±12.21* |
高剂量组 | 0.15 | 131.00±0.90* | 80.00±14.09* | 82.50±13.20* | 74.50±8.72* | 67.83±6.96* |
表5组合药物对小鼠空间探索实验逃避潜伏期及穿台次数的影响
组别 | 剂量(g/kg) | 逃避潜伏期(s) | 穿台次数(次) |
正常组 | - | 36.88±5.89 | 3.50±0.76 |
模型组 | - | 112.11±8.09<sup>##</sup> | 0.17±0.17<sup>##</sup> |
低剂量组 | 0.05 | 56.09±20.93* | 2.23±0.79* |
中剂量组 | 0.10 | 48.08±18.55* | 2.37±0.79* |
高剂量组 | 0.15 | 40.83±16.23* | 3.48±5.25 |
本发明由表4、表5可以看出,模型组逃避潜伏期明显延长,穿台次数明显减少,低剂量、中剂量和高剂量组小鼠逃避潜伏期明显缩短,穿台次数逐渐增加。
某患者,女,39岁,假日出游,日晒后颈部出现红疹,伴有瘙痒症状,经临床诊断为日光性皮炎,使用本发明组合物,一日三次空腹服用,两日后瘙痒明显减退,红疹变淡,一周后症状完全消失。
某患者,女,53岁,患有日光性皮炎,不能日晒,晒后皮肤瘙痒,略带红肿,皮肤不能暴露在阳光下,使用本发明组合物,一周后症状逐渐改善,连续服用4周后一年内未复发。次年,连续服用4周,三年未复发。
某患者,男,29岁,夏日着短裤,小腿暴露在阳光下,出现密集红疹,奇痒无比,使用本发明组合物,一周后症状消失,8年未复发。
Claims (4)
1.一种具有抗氧化活性的组合物,其特征在于,主要由以下药物配比组成:葡萄籽20%--80%,石榴籽20%--80%。
2.根据权利要求1所述的抗氧化药物组方,其特征在于,各个组分的百分比为:葡萄籽(20%--80%)、石榴籽(20%--80%),或与微晶纤维素,预胶化淀粉,大豆油,乳糖,蔗糖,糊精等辅料,制备成各种剂型。
3.根据权利要求1或2所述的一种抗氧化药物组方,其特征在于所述组合药物的剂型为散剂、片剂、颗粒剂、丸剂、胶囊剂、泡腾片、糖浆剂、膏滋、乳剂、合剂、混悬剂、缓释剂、控释剂、靶向制剂或针剂等。
4.权利要求1-3任一项所述的一种具有抗氧化活性的组合物在制备抗氧化,预防、治疗日光性皮炎,阿尔兹海默症等疾病的治疗药物或辅助治疗的功能性食品中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711430886.3A CN109954052A (zh) | 2017-12-26 | 2017-12-26 | 一种具有抗氧化活性的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711430886.3A CN109954052A (zh) | 2017-12-26 | 2017-12-26 | 一种具有抗氧化活性的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109954052A true CN109954052A (zh) | 2019-07-02 |
Family
ID=67021982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711430886.3A Pending CN109954052A (zh) | 2017-12-26 | 2017-12-26 | 一种具有抗氧化活性的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109954052A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115884780A (zh) * | 2020-05-28 | 2023-03-31 | 浦项工科大学校产学协力团 | 一种以玫瑰茄、迷迭香以及葡萄籽提取物为有效成分包含其中的神经退行性病变的预防或治疗组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105733799A (zh) * | 2016-04-15 | 2016-07-06 | 合肥珠光粮油贸易有限公司 | 一种极具抗氧化能力的米糠油 |
-
2017
- 2017-12-26 CN CN201711430886.3A patent/CN109954052A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105733799A (zh) * | 2016-04-15 | 2016-07-06 | 合肥珠光粮油贸易有限公司 | 一种极具抗氧化能力的米糠油 |
Non-Patent Citations (4)
Title |
---|
周德著: "《中老年食疗养生入门》", 30 September 2012, 北京:上海科学技术出版社 * |
王昌涛等: "《化妆品植物添加剂的开发与应用》", 30 April 2013, 北京:中国轻工业出版社 * |
练庆旺: "葡萄籽原花青素对阿尔茨海默病的作用及其机制的实验研究", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
黄晓辉等: "葡萄籽中原花青素的抗氧化性能的研究", 《宁德师范学院学报(自然科学版)》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115884780A (zh) * | 2020-05-28 | 2023-03-31 | 浦项工科大学校产学协力团 | 一种以玫瑰茄、迷迭香以及葡萄籽提取物为有效成分包含其中的神经退行性病变的预防或治疗组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6602526B2 (en) | Oral compositions containing lotus | |
US20180318320A1 (en) | Composition for preventing, alleviating or treating muscle diseases or improving muscular function | |
US20090110674A1 (en) | Health supplement | |
US20090047304A1 (en) | Composition For Body Fat Reduction | |
CN102742656B (zh) | 一种缓解视力疲劳的奶茶及其制备方法 | |
CN104855957A (zh) | 一种具有抗氧化、延缓衰老的医药保健品 | |
CN109619566A (zh) | 一种缓解视力疲劳的营养食品 | |
CN108713760A (zh) | 一种抗疲劳护眼营养液及其制备方法 | |
EP2859896B1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
US20110189319A1 (en) | Lifeforce liquid supplement | |
CN110099691A (zh) | 玛卡组合物和使用方法 | |
CN102596205B (zh) | 不易消化的寡糖的应用 | |
KR20110119305A (ko) | 타우린, 비타민류, 로얄젤리, 홍삼, 구기자, 글루메이트 (탈지미강, 미베아) 및 애플 에센스를 주성분으로 함유하는 기능성 음료조성물 | |
KR20200011442A (ko) | 루테인류 또는 그의 염 및 마름속 식물의 가공물을 함유하는, 뇌기능 장애의 예방 및/또는 개선용 조성물 | |
KR102120593B1 (ko) | 황칠을 이용한 기억력 및 인지능력 개선용 조성물 | |
US8557236B2 (en) | Cardiovascular support supplement and compositions and methods thereof | |
CN109954052A (zh) | 一种具有抗氧化活性的组合物 | |
CN105901577A (zh) | 一种脑、眼、强体营养剂及其制备方法和应用 | |
US20040258778A1 (en) | Lactation cessation and breast engorgement compositions and method of use | |
CN105477100A (zh) | 一种灵芝孢子油复方保健喷雾剂及制备方法 | |
KR101401612B1 (ko) | 석류 추출물을 유효성분으로 포함하는 스트레스성 질환의 치료 및 예방용 조성물 | |
CN107439866A (zh) | 枸杞鹰嘴豆植物营养素饮料及其制备工艺 | |
KR20190048794A (ko) | 상엽 추출물을 유효 성분으로 포함하는 근위축 예방 및 개선용 조성물 | |
CN106819223A (zh) | 一种保健奶茶及其制备方法 | |
KR101241455B1 (ko) | 혈당 강하용 두부 및 그 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190702 |
|
WD01 | Invention patent application deemed withdrawn after publication |